Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
The study showed that orelabrutinib was safe and well tolerated in participants with SLE.
The study showed that orelabrutinib was safe and well tolerated in participants with SLE.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.